Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: a cohort study using OpenSAFELY-TPP

Agnieszka Lemanska1*, Colm Andrews2, Louis Fisher2, Seb Bacon2, Amir Mehrkar2, Peter Inglesby2, Simon Davy2, Praveetha Patalay3, Ben Goldacre2, Brian MacKenna2, The OpenSAFELY Collaborative1, Alex Walker2

1Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
2Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
3Faculty of Population Health Sciences, University College London, London, UK

*Membership of the OpenSAFELY Collaborative is provided in the Acknowledgments Section

*a.lemanska@surrey.ac.uk

Abstract

Background
Healthcare across all sectors, in the UK and globally, was negatively affected by the COVID-19 pandemic. We investigated the effect of the COVID-19 pandemic on the quantity of healthcare services delivered to people with pancreatic cancer.

Methods
With the approval of NHS England, and drawing from a nationally representative OpenSAFELY-TPP dataset of 24 million patients (over 40% of the English population), we undertook a cohort study of people diagnosed with pancreatic cancer. We queried electronic healthcare records for information on the provision of healthcare services across the pancreatic cancer pathway. To estimate the effect of the COVID-19 pandemic, we predicted the rates of healthcare services if the pandemic had not happened. We used generalised linear models (GLM) and the pre-pandemic data from January 2015 to February 2020 to predict rates in March 2020 to September 2022. The 95% confidence intervals of the predicted values were used to estimate the significance of the difference between the predicted and observed rates.

Results
The rate of pancreatic cancer and diabetes diagnoses in the cohort was not affected by the pandemic. There were 24,500 people diagnosed with pancreatic cancer from January 2015 to September 2022. The mean age at diagnosis was 72 (±11 SD), 48% of people were female, 95% were of White ethnicity and 39% were diagnosed with diabetes. We found a reduction in surgical resections by nearly 25% during the pandemic. In addition, 20%, 10% and 5% fewer people received BMI, HbA1c and liver function tests respectively before they were diagnosed with pancreatic cancer. There was no impact of the pandemic on the number of people making contact with primary care, but the number of contacts increased on average by 1 to 2 per person amongst those who made contact. Abdominal scans decreased by 7% and reporting of jaundice decreased by 20%, but recovered within six months into the pandemic. Emergency department visits, hospital admissions and deaths were not affected.

Conclusions
The preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
The pandemic affected healthcare in England across the pancreatic cancer pathway. Positive lessons could be learnt from services that recovered quickly. The reductions in healthcare experienced by people with cancer have the potential to lead to worse outcomes. Current efforts should focus on addressing the unmet needs of people with cancer.

**Keywords:** Pancreatic cancer, healthcare, cancer care, COVID-19
Introduction

Cancer services were already overstretched before the COVID-19 pandemic [1, 2]. With the widespread effect on healthcare, the pandemic further exacerbated the cancer-related healthcare crisis [3-14]. During the pandemic, the resources, and the attention in healthcare systems globally, shifted towards preventing and managing COVID-19 [15, 16]. Access to the non-COVID-19-related healthcare changed [17-19], waiting times increased [20, 21], and cancer pathways including treatment standards were adapted [3-10]. In addition, patients’ healthcare-seeking behaviour changed as people adopted social distancing (limiting face to face contact) and shielding to protect themselves and healthcare systems from unprecedented pressures of the pandemic [22-24]. People were cautious and were actively taking measures to preserve healthcare and limit the spread of COVID-19 [25].

People affected by cancer were particularly vulnerable to the changes brought by the pandemic [26]. This is because they rely on healthcare. In pancreatic cancer, the challenging diagnosis (due to non-specific symptoms) and rapid progression, require an efficient system [27]. Weight loss, hyperglycaemia, diabetes, and bile duct obstruction often occur as complications of pancreatic cancer [28]. Therefore, timely assessments of body mass index (BMI), glycated haemoglobin (HbA1c) and liver function can support early diagnosis [29] and monitoring of the progression [30]. However, the negative effect of the COVID-19 pandemic resulted in delays and missed opportunities throughout the cancer pathway, which in turn affected patient outcomes including survival [6-9, 11-13, 20, 31].

To mitigate the negative effect of the COVID-19 pandemic and support patients and healthcare systems in recovery, it is important to provide the assessment of the scale of the impact. We therefore set out to investigate the effect of the pandemic on pancreatic cancer services in England. The objectives were to:

1. Access nationally representative data on healthcare services across the pancreatic cancer pathway. This was to investigate the effect of the COVID-19 pandemic on the range of services, from diagnostics to survivorship, as well as different healthcare settings including primary and secondary care.

2. Compare the quantity of healthcare that would be delivered if the pandemic had not happened (predicted based on the pre-pandemic trends) to that actually delivered (observed) during and after the pandemic. This was to assess the effect of the COVID-19 pandemic using the significance of the difference between the observed and predicted rates.

3. Access near-real time longitudinal data (up to September 2022) and analyse trends over time. This was to investigate patterns in the recovery of services from the effect of the pandemic.
Methods

Study design
This was a cohort study set in England, UK. We analysed electronic healthcare records (EHR) of adults diagnosed with pancreatic cancer between 1st January 2015 and 30th September 2022.

Data Source: OpenSAFELY-TPP dataset
We used the nationally representative OpenSAFELY-TPP dataset comprising 24 million people currently registered with primary care practices that use TPP’s SystmOne software (covering over 40% of England’s population) [32]. Linked pseudonymized EHRs included coded diagnoses, medications and physiological parameters. No free text data were available.

Primary care records managed by TPP were linked to Secondary Uses Service (SUS) hospital procedures and admissions data, and to Office of National Statistics (ONS) death data through OpenSAFELY. OpenSAFELY is an analytics platform created by our team on behalf of NHS England to address urgent COVID-19 research questions. It provides a secure software interface allowing the analysis of pseudonymized primary care records of patients from England in near real-time within the TPP’s highly secure data centre, avoiding the need for large volumes of patient data to be transferred off-site. This, in addition to other technical and organisational controls, minimises any risk of patient re-identification. Further details can be found in the information governance section of this manuscript and on opensafely.org.

Study population
The study population was derived from the OpenSAFELY-TPP dataset. Participants were adults diagnosed with pancreatic cancer between 1st January 2015 and 30th September 2022. Data on healthcare services delivered to study participants were extracted and trends over time were analysed.

Outcome measures
The information on new pancreatic cancer diagnosis (incidence) was extracted. This was defined as the first time that a clinical code for pancreatic cancer was entered in a primary care record. The age of participants at diagnosis, their gender and ethnicity were also extracted. To assess the effect of the pandemic on pancreatic cancer diagnosis, numbers of people diagnosed with pancreatic cancer were presented as monthly rates per 100,000 adults registered with TPP practices.

To analyse the effect of the COVID-19 pandemic on pancreatic cancer-related services, the episodes of care were extracted from 6 months before to 6 months after pancreatic cancer diagnosis (apart from the diabetes diagnosis which was extracted at any time). The date of pancreatic cancer diagnosis served as an index date for each participant. Table 1 presents the healthcare services included in the study, and the time windows for which they were assessed.

Data on healthcare services were assessed as monthly rates of people who received a healthcare service (≥ one episode) per 100 people diagnosed. Some services were assessed as monthly rates (numbers) of episodes per one person diagnosed (or for primary care contacts this was per person in contact).
Table 1. Healthcare services (contacts, appointments, diagnosis, diagnostic tests, routine assessments) and associated time windows for which they were extracted. Pancreatic cancer diagnosis was an index date. Counts of healthcare services were presented as either monthly rates of people who were diagnosed that month and received a healthcare service within the time window per 100 people diagnosed that month, or number of episodes received within the time window per person diagnosed each month (except for the number of primary care contacts which was analysed per person in contact).

<table>
<thead>
<tr>
<th>Healthcare service</th>
<th>Time window</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Six months before pancreatic cancer diagnosis</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Six months after pancreatic cancer diagnosis</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Primary care</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes diagnoses</td>
<td>Any time</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Contacts with primary care (these include all contact events, not only healthcare appointments)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>BMI assessments</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>HbA1c assessments</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Liver function assessments</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Reporting of jaundice</td>
<td>✓</td>
<td>X</td>
<td>✓</td>
</tr>
<tr>
<td>Pancreatic enzyme supplementation</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Secondary care</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal imaging</td>
<td>✓</td>
<td>X</td>
<td>✓</td>
</tr>
<tr>
<td>Pancreatic cancer resection (surgery)</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Emergency department visits</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hospital admissions</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>National mortality register</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death (any cause)</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Primary care data were extracted using the systematised nomenclature of medicine clinical terminology (SNOMED CT) system. Medications data, namely pancreatic enzyme supplements, were extracted using the list compiled based on the British National Formulary (BNF, bnf.org) and coded using NHS Dictionary of Medicines and Devices codes. Hospital procedures data were queried using the Office of Population Censuses and Surveys (OPCS-4) coding system.

**Study dates**

The study period was from 1st Jan 2015 to 30th September 2022. In the UK, the pandemic-related restrictions started in March 2020 with the first national lockdown in England commencing on 26th March 2020, and the two consecutive lockdowns starting 5th November 2020 and 6th January 2021. From 8th March 2021, governments in the UK began a phased exit from the third and final lockdown. Therefore, to analyse the effect of the COVID-19 pandemic, three separate periods were adopted. The period before the pandemic was from 1st January 2015 to 29th February 2020. The lockdown period was from 1st March 2020 to 31st March 2021. The recovery period (the period of easing restrictions) was from 1st April 2021 to 30th September 2022. The recovery period was censored six months earlier, by 31st March 2022, for the outcomes that assessed healthcare service six months after pancreatic cancer diagnosis. This was to ensure completeness of six months follow-up data.
Primary care data were available for the whole study period. However, secondary care data were only available from January 2017 onwards. Emergency department visits as well as ONS mortality data were available from January 2019 onwards.

**Statistical analysis**

Counts of patients and healthcare services were rounded to the nearest 5 to comply with the rules for preventing statistical disclosure. The observed monthly rates were visualised between 1st January 2015 (or as available) and 30th September 2022 (or 31st March 2022 for the outcomes that assessed healthcare within six months after pancreatic cancer diagnosis).

Data from before the pandemic were used to predict monthly rates of healthcare services that would be expected during the lockdown and recovery periods if the pandemic had not happened. Generalised linear models (GLM) were used to model monthly rates. A separate model was fitted for each healthcare service. An interrupted time series approach was used to predict the expected rates in the lockdown and recovery periods. To account for seasonality in data, calendar months were fitted as a categorical variable. To allow for change in healthcare services over time, the time was fitted as a continuous variable. Two dummy variables for the two COVID-19 periods were included to allow trends and slopes to vary in these periods separately.

The differences between the observed and predicted rates were calculated and presented as the percentage change from the predicted. The 95% confidence intervals of the predicted values were used to estimate the significance of the difference between the predicted and observed values (to estimate the effect of the COVID-19 pandemic). The average values across periods (rather than any specific points in time) were used to estimate the overall effect in each period.

**Software and reproducibility**

Data management was performed in SQL and Python version 3.8. Statistical analyses were performed in R version 4.0.2 using packages MASS for GLM and ggplot2 for data visualisation. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) guidelines were followed [33]. Software for data analysis and code lists used to define outcome measures are available from github.com/opensafely/Pancreatic_cancer.

**Results**

**Study population and participants**

In total, there were 24,500 people diagnosed with pancreatic cancer in the study period (study participants). On average, there were 263 (±24 SD) pancreatic cancer diagnosis each month. The mean age at pancreatic cancer diagnosis was 72 (±11 SD). 11,850 (48%) participants were females and 12,645 (52%) were males. 16,870 participants were of white ethnicity (95% for which ethnicity data were recorded). Ethnicity data were missing for 6,685 (27%) participants. 9670 (39%) of people with pancreatic cancer received diagnosis of diabetes at some point before or after their diagnosis.

**The effect of COVID-19 on pancreatic cancer and diabetes diagnosis**

We did not observe an effect of the COVID-19 pandemic on pancreatic cancer diagnosis (Figure 1A). For every 100,000 registered people, there was 1 pancreatic cancer diagnosis a month in the lockdown and in the recovery period. This equated to the predicted rate of 1 (95% CI: 1 to 2) in both periods of the pandemic (Table 2). We also did not observe an effect on diabetes diagnosis in this cohort (Figure 1B). In both periods of the pandemic, 41% of people received diabetes diagnosis. The
predicted rates per 100 diagnosed people were 41 (95% CI: 38 to 44) in the lockdown period and 42 (95% CI: 39 to 45) in the recovery period.

Figure 1. Observed and predicted monthly rates (as if the COVID-19 pandemic had not happened) for A) pancreatic cancer diagnosis per 100,000 registered patients, and B) diabetes diagnosis per 100 people with pancreatic cancer.
Table 2. Statistical significance of the differences between the observed and predicted monthly rates of healthcare services with 95% confidence intervals. Values were predicted based on the pre-pandemic period from 1st January 2015 to 29th February 2020. The lockdown period was from 1st March 2020 to 31st March 2021. The recovery period (the period of easing restrictions) was from 1st April 2021 to 30th September 2022 or to 31st March 2022 (for healthcare services that were evaluated six months after diagnosis). The values are the average monthly rates over the period. Unless otherwise specified, the rates are per 100 people diagnosed with pancreatic cancer. *Indicates statistical significance with 95% confidence levels.

<table>
<thead>
<tr>
<th></th>
<th>Lockdown period: 1st March 2020 to 31st March 2021 (13 months)</th>
<th>Recovery period: 1st April 2021 to 31st March 2022 or 30th September 2022 (12 months or 18 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Predicted rates (95% CI) Observed rates Difference</td>
<td>Predicted rates (95% CI) Observed rates Difference</td>
</tr>
<tr>
<td><strong>Pancreatic cancer diagnosis</strong></td>
<td>1 (1 to 2) 1 0 (2%)</td>
<td>1 (1 to 2) 1 0 (5%)</td>
</tr>
<tr>
<td><strong>Diabetes diagnosis</strong></td>
<td>41 (38 to 44) 41 0 (0%)</td>
<td>42 (39 to 45) 41 -1 (1%)</td>
</tr>
<tr>
<td>before or after</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>People with ≥ 1 primary care contacts within six months before pancreatic cancer diagnosis</strong></td>
<td>93 (92 to 95) 92 -2 (2%)</td>
<td>98 (95 to 100) 95 -2 (2%)</td>
</tr>
<tr>
<td><strong>People with ≥ 1 primary care contacts within six months after pancreatic cancer diagnosis</strong></td>
<td>88 (85 to 91) 89 1 (1%)</td>
<td>92 (89 to 95) 92 1 (1%)</td>
</tr>
<tr>
<td><strong>Number of primary care contacts within six months before pancreatic cancer diagnosis (per person in contact)</strong></td>
<td>11 (10 to 12) 12 1 (8%) *</td>
<td>11 (10 to 12) 13 2 (15%) *</td>
</tr>
<tr>
<td><strong>Number of primary care contacts within six months after pancreatic cancer diagnosis (per person in contact)</strong></td>
<td>11 (10 to 11) 12 2 (18%) *</td>
<td>11 (10 to 11) 12 1 (14%) *</td>
</tr>
<tr>
<td><strong>People with ≥ 1 BMI assessments within six months before pancreatic cancer diagnosis</strong></td>
<td>55 (52 to 59) 44 -12 (21%) *</td>
<td>57 (53 to 61) 47 -10 (17%) *</td>
</tr>
<tr>
<td><strong>People with ≥ 1 BMI assessments within six months after pancreatic cancer diagnosis</strong></td>
<td>31 (28 to 34) 25 -5 (18%) *</td>
<td>33 (29 to 36) 30 -2 (6%)</td>
</tr>
<tr>
<td><strong>People with ≥ 1 HbA1c assessments within six months before pancreatic cancer diagnosis</strong></td>
<td>61 (57 to 64) 55 -6 (10%) *</td>
<td>65 (61 to 69) 60 -5 (8%) *</td>
</tr>
<tr>
<td><strong>People with ≥ 1 HbA1c assessments within six months after pancreatic cancer diagnosis</strong></td>
<td>19 (16 to 21) 16 -2 (12%)</td>
<td>19 (17 to 22) 19 -1 (4%)</td>
</tr>
<tr>
<td><strong>People with ≥ 1 liver function assessments within six months before pancreatic cancer diagnosis</strong></td>
<td>80 (77 to 83) 76 -4 (5%) *</td>
<td>81 (78 to 84) 77 -3 (4%)</td>
</tr>
<tr>
<td><strong>People with ≥ 1 liver function assessments within six months after pancreatic cancer diagnosis</strong></td>
<td>33 (31 to 36) 33 0 (1%)</td>
<td>32 (29 to 35) 34 1 (4%)</td>
</tr>
<tr>
<td>Event</td>
<td>Before PC Diagnosis</td>
<td>Before/After</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>People reporting jaundice ≥ 1 times within six months before PC</td>
<td>10 (8 to 11)</td>
<td>7</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>People receiving abdominal scan ≥ 1 times within six months before PC</td>
<td>30 (27 to 34)</td>
<td>28</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>People receiving ≥ 1 prescriptions for enzyme supplements within six months after PC</td>
<td>55 (52 to 58)</td>
<td>54</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>People receiving pancreatic cancer resection within six months after PC</td>
<td>8 (6 to 9)</td>
<td>6</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of emergency department visits within six months before PC (per person diagnosed)</td>
<td>1 (1 to 1)</td>
<td>1</td>
</tr>
<tr>
<td>Number of emergency department visits within six months after PC (per person diagnosed)</td>
<td>1 (0 to 1)</td>
<td>1</td>
</tr>
<tr>
<td>Number of hospital admissions within six months before PC (per person diagnosed)</td>
<td>2 (2 to 2)</td>
<td>2</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of hospital admissions within six months after PC (per person diagnosed)</td>
<td>4 (4 to 4)</td>
<td>4</td>
</tr>
<tr>
<td>pancreatic cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>People who died within six months after pancreatic cancer diagnosis</td>
<td>56 (47 to 66)</td>
<td>55</td>
</tr>
</tbody>
</table>
Primary care contacts

The number of people with pancreatic cancer who contacted primary care before and after their diagnosis, increased over time, from 70% and 80% (respectively) in 2015 to over 90% by 2022 (Figure 2A and B). This trend was not affected by the pandemic (Table 2). We observed that 92% (predicted 93% [95% CI: 92 to 95]) of people diagnosed in the lockdown period, contacted (≥ 1 contact) primary care within six months before they were diagnosed, and 89% (predicted 88% [95% CI: 85 to 91]) contacted primary care within six months after diagnosis. In the recovery period this was 95% (predicted 98% [95% CI: 95 to 100]) and 92% (predicted 92% [95% CI: 89 to 95]) respectively.

However, there was a difference in the number of primary care contacts recorded per person. People diagnosed in the lockdown period had on average 1 contact more than predicted (12 vs 11 [95% CI: 10 to 12]) within six months before the diagnosis and 2 contacts more than predicted (12 vs 11 [95% CI: 10 to 11]) within six months after they were diagnosed. This was similar for people diagnosed in the recovery period. For these people, there were 2 more contacts observed than predicted (13 vs 11 [95% CI: 10 to 12]) before the diagnosis and 1 (12 vs 11 [95% CI: 10 to 11]) after the diagnosis (Table 2).
Figure 2. The observed and predicted (as if the COVID-19 pandemic had not happened) monthly rates of A) people in contact with primary care before pancreatic cancer diagnosis, B) people in contact with primary care after pancreatic cancer diagnosis. Rates are per 100 people diagnosed with pancreatic cancer. C) and D) are monthly rates of primary care contacts per person before and after pancreatic cancer diagnosis. Contacts with primary care include all contact events (all reasons and purposes), not only healthcare appointments.
BMI, HbA1c and liver function assessments

In both periods of the pandemic, we observed reductions in numbers of people receiving BMI, HbA1c and liver function assessments before they were diagnosed with pancreatic cancer (Figure 3). For BMI, these were 21% and 17% less people than predicted received at least one assessment in the lockdown and recovery periods respectively. For HbA1c these were 10% and 8% reductions and for liver function these were 5% and 4% reductions respectively (Table 2). Except for BMI, we did not observe reductions in numbers of people receiving these assessments after they were diagnosed with cancer.
Figure 3. The observed and predicted (if the COVID-19 pandemic had not happened) monthly rates of A) and B) people with at least one BMI assessment before and after pancreatic cancer diagnosis, and C) and D) people with at least one HbA1c assessment before and after pancreatic cancer diagnosis. All rates are per 100 people diagnosed with pancreatic cancer.
Symptoms and treatments

The reporting of jaundice in primary care and abdominal imaging in secondary care were reduced for people diagnosed in the lockdown period. For every 100 people diagnosed in the lockdown period, two (25%) less people (7 vs 10 [95% CI: 8 to 11] predicted) reported jaundice before they were diagnosed (Table 2). For abdominal imagining the observed in the lockdown period average reduction of 7% (28 vs 30 [95% CI: 27 to 34] predicted) did not reach statistical significance. The reductions in both services were transient. They recovered to the pre-pandemic levels by May 2021 (jaundice) and by Aug 2020 (abdominal imaging) (Figure 4A and B).

Figures 4C and D represent two pancreatic cancer treatments. The prescribing of pancreatic enzyme replacement in primary care was not affected by the pandemic. However, pancreatic cancer resection (surgery) was significantly affected in both periods of the pandemic. We estimated that for every 100 people diagnosed, 6 people received the treatment in the pandemic. This was two people less than predicted 8 (95% CI: 6 to 9) in the lockdown period and 9 (95% CI: 7 to 11) in the recovery period and represented an over 25% reduction in the number of people who received surgical resection during the pandemic as compared to what would be expected based on the pracademic trends.
Figure 4. The observed and predicted (as if the COVID-19 pandemic had not happened) monthly rates of people A) reporting jaundice before the diagnosis, B) receiving abdominal imaging assessment before the diagnosis, C) receiving pancreatic enzyme supplementation after the diagnosis, and D) pancreatic resection within after the diagnosis.
Emergency department visits, hospital admissions and deaths

In the cohort of people diagnosed with pancreatic cancer, we found no effect of the COVID-19 pandemic on the number of emergency department visits, hospitalisations within six months before or six months after pancreatic cancer diagnosis, and deaths within six months after pancreatic cancer diagnosis (Figure 5). The rates did not differ from what would be expected if the pandemic had not occurred (Table 2). The decrease in rates of deaths toward the end of the study period, visible from the graph, is most likely due to delays in deaths being entered into the registry data [34].
Figure 5. The observed and predicted (as if the COVID-19 pandemic had not happened) monthly rates of episodes per 1 participant diagnosed with pancreatic cancer, A) emergency department visits within six months before the diagnosis, B) emergency department visits within six months after, C) hospital admissions within six months before, D) hospital admissions within six months after, and E) deaths within six months after per 100 people diagnosed with pancreatic cancer.
Discussion

Summary and findings in context

We found that many of the pancreatic cancer-related services were disrupted across the pathway of care. This is in line with previous reports about healthcare being negatively affected by the COVID-19 pandemic [3-9, 11-14]. Healthcare assessments, such as BMI, HbA1c and liver function, were delivered to fewer people than would be expected if the pandemic had not occurred. This could impair not only the early diagnosis of pancreatic cancer, but also diagnosis of other diseases such as diabetes [29]. In addition, this could have implications for the quality of routine data for research [29, 35, 36].

Disappointingly, we observed that by Sept 2022, two and a half years into the pandemic, pre-pancreatic cancer diagnosis testing of BMI, HbA1c and liver function did not recover to the pre-pandemic levels. However, reassuringly, for people who received pancreatic cancer diagnosis, primary care healthcare in this area was resilient. The effect of the pandemic on these tests for people already diagnosed was more transient, and after an initial drop, the levels recovered by six months into the pandemic. More reassuringly also, other services that recovered quickly after the initial decrease, were consultations for jaundice in primary care and abdominal imaging in secondary care. It has been previously reported that many non-emergency diagnostic services, such as abdominal imaging, were suspended during the first peak of the pandemic, but they gradually reopened starting from July 2020 following publications of infection control guidelines [37].

Pancreatic cancer diagnosis was not affected. This is a positive finding but sets pancreatic cancer apart from the other major cancer sites such as breast [4, 5], prostate [4, 19], or colorectal [4-6, 19, 20]. This may be because pancreatic cancer does not rely on screening programs and diagnostic services in primary care, with emergency presentations remaining the main route of diagnosis [38]. Also contrary to the evidence from other patient groups, in this cohort, we did not find an effect of the COVID-19 pandemic on diabetes diagnosis. While in the general population, there was a significant reduction in diabetes diagnosis and management services [39].

Most people (over 90%) were in contact with primary care before and after pancreatic cancer diagnosis. The pandemic did not affect this. However, we observed that the number of contacts increased on average by 1 or 2 per person as compared to the pre-pandemic levels. This may reflect a true increase of contacts as primary care transitioned to remote consulting with an increased role of telephone triage [40]. However, this may also reflect increased recording of contacts in electronic health records as practices responded to the pandemic using different online systems with automated code recording activity [41]. Remote consulting offers an important advantage for improved efficiency and access not only during pandemics [42]. However, it has been shown that for complex conditions, remote consulting can be a more time-consuming approach, increasing workload with subsequent follow-up appointments [43, 44].

Strengths and limitations

The OpenSAFELY-TPP dataset, a population-based and nationally representative dataset of an unprecedented size and completeness is the key strength of this study [32]. Also the cohort study design is a strength because we were able to focus specifically on people affected by pancreatic cancer, rather than investigate the already well known effect of COVID-19 on general practice [45]. The interrupted time series approach and modelling COVID-19 rates has an advantage over simply
compared COVID-19 rates to pre-COVID rates. This is because we could account for long-term trends and seasonal variation in healthcare data. We used data dating back to 2015 to model the trends which made the prediction of expected rates more accurate. This provides a less-biased estimate of the effect of the pandemic. The near real-time data available via OpenSAFELY enabled us to investigate the most recent trends and recovery from the pandemic. In addition, the automated audit of healthcare services that we have developed within the OpenSAFELY, can enable regular updates of data. All analytics software and code lists are shared openly and are available for inspection and re-use, providing opportunity for reproduction of this report and reducing duplicative efforts.

We also note some limitations. Lists of clinical codes used to extract data may not be exhaustive and may miss episodes of care. Pancreatic cancer case ascertainment was via coding in primary care, rather than via linkage with cancer registry (the gold standard data source for cancer diagnoses). It is possible that with this approach some pancreatic cancer cases could have been missed or miscoded. However, in the UK, the information about cancer diagnosis is sent to primary care within the hospital discharge letters and primary care is a valid source of data [46]. In addition, the incidence rates in this study aligned with the published rates validating good ascertainment of cases.

Policy Implications and future research

Considering the worsening healthcare crisis, it is important to continue monitoring services to ensure the quality of healthcare and recovery from the pandemic. As we innovate and adapt healthcare, with infection control measures, digital health approaches and increasing remote consulting, it is important to evaluate the impact on cancer management. In addition, more research is needed to investigate how these changes affected different groups of patients. The pandemic exacerbated healthcare inequalities [14] and future work should include stratified analysis investigating different socio-demographic groups.

Conclusions

COVID-19 was an unprecedented global event, adding pressures to already overburdened healthcare systems, further exacerbating healthcare crises. Positive lessons could be learnt from resilient healthcare services which continued to deliver healthcare undisrupted, or those initially affected, as they implemented active measures to recover the volume of care quickly and safely. On the other hand, the reductions in healthcare experienced by people with non-COVID-19 illnesses, bolster the argument that efforts should focus on addressing the unmet needs of people with cancer.
Declarations

Acknowledgements

We are very grateful for all the support received from the TPP Technical Operations team throughout this work, and for generous assistance from the information governance and database teams at NHS England and the NHS England Transformation Directorate.


Conflicts of Interest

BG received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, NHS England, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI MRC, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he is a Non-Executive Director at NHS Digital; he also receives personal income from speaking and writing for lay audiences on the misuse of science. BMK is employed as a pharmacist by NHS England and seconded to the Bennett Institute.

Funding statement

This work was jointly funded by the Wellcome Trust (222097/Z/20/Z); MRC (MR/V015757/1, MC_PC-20059, MR/W016729/1); NIHR (NIHR135559, COV-LT2-0073), and Health Data Research UK (HDRUK2021.000, 2021.0157).

This work was funded by Medical Research Council (MRC) grant reference MR/W021390/1 as part of the postdoctoral fellowship awarded to AL and undertaken at the Bennett Institute, University of Oxford.

The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, UK Health Security Agency (UKHSA) or the Department of Health and Social Care.

Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Ethical approval

The study was approved by the Health Research Authority (Research Ethics Committee reference 20/LO/0651) and the London School of Hygiene and Tropical Medicine (London, UK) Ethics Board (reference 21863).

Information governance

NHS England is the data controller for OpenSAFELY-TPP; TPP is the data processor; all study authors using OpenSAFELY have the approval of NHS England. This implementation of OpenSAFELY is hosted...
within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant [47].

Patient data have been pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, restricted to a small group of researchers; the researchers hold contracts with NHS England and only access the platform to initiate database queries and statistical models; all database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts [48].

The OpenSAFELY research platform adheres to the obligations of the UK General Data Protection Regulation (GDPR) and the Data Protection Act 2018. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process confidential patient information for the purposes of protecting public health, providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents of exposure; this sets aside the requirement for patient consent [49].

Taken together, these provide the legal bases to link patient datasets on the OpenSAFELY platform. Primary care practices, from which the primary care data are obtained, are required to share relevant health information to support the public health response to the pandemic and have been informed of the OpenSAFELY analytics platform.

**Data access and verification**

Access to the underlying identifiable and potentially re-identifiable pseudonymised electronic health record data is tightly governed by various legislative and regulatory frameworks and restricted by best practice. The data in OpenSAFELY is drawn from General Practice data across England where TPP is the data processor. TPP developers initiate an automated process to create pseudonymised records in the core OpenSAFELY database, which are copies of key structured data tables in the identifiable records. These pseudonymised records are linked onto key external data resources that have also been pseudonymised via SHA-512 one-way hashing of NHS numbers using a shared salt. Bennett Institute for Applied Data Science developers and PIs holding contracts with NHS England have access to the OpenSAFELY pseudonymised data tables as needed to develop the OpenSAFELY tools. These tools in turn enable researchers with OpenSAFELY data access agreements to write and execute code for data management and data analysis without direct access to the underlying raw pseudonymised patient data, and to review the outputs of this code. All code for the full data management pipeline—from raw data to completed results for this analysis—and for the OpenSAFELY platform as a whole is available for review at github.com/OpenSAFELY. The data management and analysis code for this paper was led by AL and contributed to by CA.

**Data Sharing**

Detailed pseudonymised patient data are potentially re-identifiable and therefore not shared. The process for external users to request access to data via the OpenSAFELY platform is described on opensafely.org.
References


